In contrast to anti-dsDNA+ SLE patients, anti-ENA+ patients show increased expression of complement regulatory molecule CD46, CD55, CD59 and ITGB2, ITGAX thus affecting complement signaling. Here, ITGB2 is linked to systemic lupus erythematosus.